PMID: 11898921Mar 20, 2002Paper

Sustained normalization of cerebral blood-flow after iloprost therapy in a patient with neuropsychiatric systemic lupus erythematosus

Lupus
A MathieuM Piga

Abstract

We report the case of a 30-year-old caucasian woman affected by SLE who developed neurological symptoms (prosopagnosia and visual-spatial agnosia) after nine years of disease. Brain MRI showed no abnormalities while a brain SPECT scan showed diffuse uptake defects and hypoperfusion areas in the right and left frontal-parietal regions. At that time the patient was on hydroxychloroquine (400 mg/day) and oral prednisolone (0.5 mg/kg/day) as maintenance therapy. One year later the patient showed worsening of Raynaud's phenomenon with digital dystrophic lesions and was therefore treated with an intravenous infusion of Iloprost (1.5 ng/kg/min per 6h/day for 10 days consecutively), while baseline treatment remained unchanged. One month later the patient showed a dramatic improvement in her cognitive function and subsequent SPECT scans showed the gradual disappearance of perfusion abnormalities. This first report of Iloprost treatment in CNS lupus suggests the potential therapeutic usefulness of this drug in patients with SLE and functional CNS involvement.

References

Aug 1, 1979·Clinical Immunology and Immunopathology·R J HarbeckD W Shucard
Feb 1, 1990·Annals of the Rheumatic Diseases·R A FieldsA D Bankhurst
Jan 1, 1986·European Journal of Clinical Pharmacology·W Krause, T Krais
Sep 1, 1988·Brain, Behavior, and Immunity·S D DenburgJ A Denburg
Jun 1, 1981·Naunyn-Schmiedeberg's Archives of Pharmacology·K SchrörR Ohlendorf
Mar 1, 1995·Annals of the Rheumatic Diseases·G A Bruyn
Jan 1, 1995·Scandinavian Journal of Rheumatology·J A DenburgH Szechtman
May 1, 1996·Annals of Internal Medicine·H OlschewskiW Seeger
Apr 1, 2000·Lancet·A MathieuM Piga

❮ Previous
Next ❯

Citations

Oct 7, 2008·Arthritis Research & Therapy·Marcus JägerRüdiger Krauspe
Mar 24, 2006·Medical Hypotheses·Daniel A Rossignol, Lanier W Rossignol
Sep 10, 2005·Best Practice & Research. Clinical Rheumatology·Pamela L PetersonDavid Isenberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.